

MedPath GmbH, Mies-van-der-Rohe-Straße 8, 80807 Munich, Germany

To whom it may concern

### MedPath GmbH

Mies-van-der-Rohe-Straße 8, 80807 Munich, Germany

Telefon: +49(0)89 189174474 Telefax: +49(0)89 5485 8884 E-Mail: info@medpath.pro

Munich, 03.07.2020

### Confirmation of EU Medical Device(s) Notification

This is to confirm that in accordance of Article 10 of Directive 98/79/EC concerning in vitro Diagnostic Medical Devices (IVDD), MedPath GmbH agrees to perform all duties and responsibilities as the Authorized Representative for the manufacturer

### Hunan Runmei Gene Technology Co., Ltd.

Room 401-1, Building 3, Shanhe Medical and Health Industrial Park, No. 1048, Zhongqing Road, Shaping Street, Kaifu District, 410153 Changsha, Hunan Province, China.

as stipulated and demanded by the aforementioned Directive. The German Competent Authority is notified of the manufacturer's medical device(s)

New Coronavirus COVID-19 Nucleic Acid Detection Kit (Fluorescent RT-PCR Method)

Registration No. in DIMDI Database System: DE/CA61/221

The manufacturer has provided MedPath GmbH with the appropriate Declaration(s) of Conformity claiming that the medical device(s) fulfills/fulfill the applicable requirements of the aforementioned Directive.

Safety Office Mies-van-der-Rohe-Strasse 8 · D-80807 München

Tel.089-189174474 · Fax 089-54858884

MedPath GmbH

BANK: Postbank

**BIC: PBNKDEFF** 

IBAN: DE06 7601 0085 0134 4418 55

St.Nr.: 143/161/40603

HRB 235061

Ust-IdNr.: DE313841775

### EC DECLARATION OF CONFORMITY

CE

Manufacturer Address

Manufacture Name: Hunan Runmei Gene Technology Co.,

Ltd.

Post Add: Room 401-1, Building 3, Shanhe Medical and Health Industrial Park, No. 1048, Zhongqing Road, Shaping Street, Kaifu District, Changsha, Hunan Province, China.

410153

European

Representative

Authorized Representative Name: Lotus NL B.V.

Add: Koningin Julianaplein 10, 1e Verd, 2595AA,

The Hague, Netherlands.

Product Information Product Name: Virus Nucleic Acid Extraction Kit or Nucleic

Acid Detection Kit

Cat. No.: RM-B

Specification: 48 Tests/kit, 96 Tests/kit

Classification

Others

**Conformity Assessment** 

Route: Annex III

We, Hunan Runmei Gene Technology Co., Ltd, under our sole responsibility declare that the above-mentioned products meet

the provisions of the following EC Council Directives and

Standards. All supporting documentations are retained under

the premises of the manufacturer.

General
Applicable
Directives

In vitro diagnostic medical devices directive:

DIRECTIVE 98/79/EC OF THE EUROPEAN PARLLAMENT AND OF

THE COUNCIL OF 27 October 1998 on in vitro diagnostic

medical devices.

**Standards Applied** 

EN 13612:2002/AC:2002

EN ISO 13485:2016

EN ISO 14971: 2012

EN ISO 23640:2015

EN ISO 18113-1: 2011

EN ISO 18113-2 2001

EN ISO 15223-1: 2016

EN 13641: 2002

Place: Changsha City, Hunan Province, China.

Name: Jian Gong

Date: May 22, 2020

Position: Managing Director

Signature:



> Retouradres Postbus 16114 2500 BC Den Haag

Lotus NL B.V. T.a.v. de heer X. Wei Koningin Julianaplein 10 2595 AA 's-Gravenhage

Datum: 11 mei 2020

Betreft: aanmelding In-vitro diagnostica

Geachte heer Wei,

Op 29 april 2020 ontving ik uw notificatie krachtens artikel 4, eerste lid van het Nederlandse Besluit in-vitro diagnostica (BIVD) om onder de bedrijfsnaam Hunan Runmei Gene Technology Co., Ltd met Europees gemachtigde Lotus NL B.V. onderstaand product als in-vitro diagnosticum op de Europese markt te brengen.

Het product staat geregistreerd als in-vitro diagnosticum onder nummer:

New Coronavirus COVID-19 Nucleic Acid Detection Kit (Fluorescent RT-PCR Method), New Coronavirus COVID-19 Antibody Detection Kit (Colloidal Gold), Virus Nucleic Acid Extraction Kit or Nucleic Acid Detection Kit, Single-use Samplers

(geen merknaam) (NL-CA002-2020-50915)

Hiermee heeft u voldaan aan uw verplichting op grond van artikel 4, BIVD.

In alle verdere correspondentie betreffende bovenvermeld product verzoek ik u dit nummer te vermelden. Aan dit nummer kunnen geen verdere rechten ontleend worden, het dient alleen om de notificatie administratief te vergemakkelijken.

De registratie van in-vitro diagnostica als medisch hulpmiddel op grond van de Classificatiecriteria (Bijlage II) bij Richtlijn 98/79/EG betreffende medische hulpmiddelen voor in-vitro diagnostiek is onderhevig aan mogelijke revisies van Europese regelgeving inzake de classificatie van medische hulpmiddelen en aan voortschrijdend wetenschappelijk inzicht (zie artikel artikel 10, eerste lid van Richtlijn 98/79/EG).

Farmatec

Bezoekadres: Hoftoren Rijnstraat 50 2515 XP Den Haag

T 070 340 6161

http://hulpmiddelen.farmatec.nl

Inlichtingen bij:

R.A.C. Ori

medische\_hulpmiddelen@ minvws.nl

Ons kenmerk: CIBG-20201800

Bijlagen

Uw aanvraag 29 april 2020

Correspondentie uitsluitend richten aan het retouradres met vermelding van de datum en het kenmerk van deze brief. Notificatie van in-vitro diagnostische medische hulpmiddelen impliceert dat de fabrikant, Hunan Runmei Gene Technology Co., Ltd de CE-conformiteitsmarkering heeft aangebracht op het desbetreffende product alvorens het in een EU-lidstaat in de handel te brengen. Zodoende garandeert Lotus NL B.V. dat het in-vitro diagnosticum voldoet aan de essentiële eisen zoals opgenomen in bijlage I bij Richtlijn 98/79/EG (en in het daarmee corresponderende onderdeel 1 bij het besluit)

Volledigheidshalve wijzen wij u erop dat een in-vitro diagnosticum moet voldoen aan de eisen uit het BIVD. Het BIVD is gebaseerd op Richtlijn voor in-vitro diagnostiek, 98/79/EG. Met name wijzen wij u op de Nederlandse-taaleis zoals deze in Nederland geldt, de eisen voor het ter beschikking houden van de technische documentatie en de plicht tot het hebben van een Post Marketing Surveillance- en vigilantiesysteem.

Tot slot merk ik op dat met uw notificatie - de administratieve notificatie als fabrikant - en deze brief geen sprake is van een oordeel over de status of kwalificatie van uw product: notificering betekent niet dat daadwerkelijk sprake is van een in-vitro diagnosticum in de zin van de onderhavige wet- en regelgeving. In voorkomende gevallen kan de Inspectie Gezondheidszorg en Jeugd (IGJ), belast met het toezicht op de naleving van het bij of krachtens de wet bepaalde, een standpunt innemen over de status van een product, waarbij het volgens vaste jurisprudentie uiteindelijk aan de nationale rechter is om te bepalen of een product onder de definitie van in-vitro diagnosticum valt.

De Minister voor Medische Zorg en Sport, namens deze,

Afdelingshoofd

Farmatec

Or. M.J. van de Velde

Dhr. M.J. van de Velde

SARS-CoV-2 (COVID-19) IgG Antibody Detection Kit (ELISA) SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA)



Hunan Runmei Gene Technology Co., Ltd.

Phone: (+86)-731-89919680/+(86)-18601454556


Email: sales@runmeigene.com

### SARS-CoV-2 (COVID-19) IgG Antibody Detection Kit (ELISA) SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA)


1. Product Picture	1
2. Operation Procedure	2-5
3. Declaration of Manufacturer's Qualification	6-12
4. CE Certification	13-14
5. SGS Report	15-31

### **Product Features**

### SARS-CoV-2 (COVID-19) IgG Antibody Detection Kit (ELISA)



SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA)



Hunan Runmei Gene Technology Co., Ltd.

### **User Manual**















SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA)

SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA)

## PACKING SPECIFICATION

96 tests/kit

### INTENDED USE

The SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA) is an Enzyme-Linked Immunosorbent Assay (ELISA) ntended for qualitative detection of total antibodies (IgM) to SARS-CoV-2 in human serum run manually. This kit is used for ssisted diagnosis

### MAIN COMPONENTS

11	10	9	88	7	6	51	4	3	2	1	Number
Instructions	Microplate Sealers	Microtiter plate	Negative Control	Positive Control	Stop Solution	Chromogenic Reagent B	Chromogenic Reagent A	20X Wash Buffer Concentrate	Specimen Diluent	Enzyme Conjugate	Composition
1	2	96T×2	1.5 ml×1 (transparent lid)	1.5 ml×1 (red lid)	11ml×1(brown lid)	11ml×1(brown lid)	11ml×1(white lid)	40ml×2(white lid)	26ml×1(yellow lid)	22ml×1(red lid)	96 Testing Kits/box

### STORAGE CONDITIONS

This product is ready for use and no further preparation is necessary. The product should be stored in its original container at 2-8°C until used. Do not overheat. Do not incubate or freeze prior to use. Improper storage will result in a loss of efficacy. Do not use after expiration date, which is clearly printed on the outer box and on each individual sterile collection unit and the

> specimen transport tube label. The unopened reagents are stable until the expiration date when stored at 2 to 8°C, and the opened kit is stable for up to 1 month from the date of opening at 2 to 8°C.

## SAMPLE REQUIREMENTS

## Applicable sample types: Serum

## Handling and storage of samples:

- Follow procedures within your laboratory to avoid cross contamination of patient specimens.
- $\cdot$  Samples may be stored at room temperature (15-30°C) for no longer than 8 hours. If the test will not be completed within 8 hours, refrigerate the serum samples at 2-8°C for no longer than 48 hours.
- Samples that will not be tested within the time frames outlined above should be stored at ≤ -20°C and may be subjected to 1
- As an alternative to the above, sample stability may be established by each laboratory

Collect whole blood in a serum separator tube (SST) or a red top or equivalent tube appropriate for isolation of serum. Refer to the serum collection tube manufacturer's instructions for serum preparation, including centrifugation

It is important to immediately transfer the liquid component (serum) after serum preparation into a clean polypropylene tube sized aliquots, stored at -20°C or lower if exceeding 9 days. It is important to avoid freeze-thaw cycles because this may be If the serum is not analyzed immediately, the serum should be kept at 2-8°C for up to 48 hours, apportioned into preferred detrimental to serum components. Samples which are hemolyzed, icteric or lipemic can invalidate certain tests

- l. Bring reagents to room temperature (15-30°C) for at least 30 minutes before use
- Allow for eight Blank/Control determinations (two Reagent Blank, two Negative Control, two Low Positive Control and two
- A full or partial plate may be run. Store the residual strips from a partial plate run in the original pouch and seal the entire opening with adhesive tape. Do not use broken strips.
- 4. Determine the volume of 1X Wash Buffer needed for the run. 24 mL total of 1X Wash Buffer is needed for each full strip of purified water thoroughly in an appropriately sized container to achieve homogeneity. The 1X Wash Buffer may be stored at 2-8°C for up to 30 days. for use with manual or automated wash. To prepare a 1X Wash Buffer, mix 1 part of the 20X Wash Buffer with 19 parts of controls and/or samples run. Volume to be prepared is  $(24\,\mathrm{mL}~\mathrm{x}~\mathrm{\#}~\mathrm{strips})$  plus sufficient excess to ensure adequate quantity
- 5. For control wells, add 50  $\mu$ L control solution directly to individual wells (except for the two Reagent Blank wells).
- 6. For sample wells, add 50 µL sample serum to each well
- 7. Mix well by gentle shaking cover the microplate wells with an adhesive sealer, and incubate for 30 minutes at  $37\pm2^{\circ}\text{C}$ .
- Microplate Washing: discard the liquid in the wells then fill each microwell with 300 μL of working Wash Buffer (1X). Leave preceding manual wash may be performed with an automated plate washer. washes. Firmly tap the inverted microplate on absorbent paper to thoroughly remove all residual liquid from the wells. The the wash buffer in each well for 5 seconds and then remove the wash solution from all the wells. Repeat 4 times for a total of 5
- 9. Add  $100\,\mu\mathrm{L}$  of the Enzyme Conjugate to each well at the same rate and in the same order as the samples. Cover the microplat with an adhesive sealer and incubate for 30 minutes at  $37\pm2^{\circ}$ C.
- 10. Microplate Washing: wash the microwells by following the procedure as described in step 8.

  11. Add 50 µL each (100 µL total) of Chromogenic Reagent A and Chromogenic Reagent B, to each well at the same rate and in the same order as the addition of the patient specimens. Mix well by gentle shaking, cover the microplate with an adhesive
- 12. Add  $50 \,\mu$ L of Stop Solution to each well at the same rate and in the same order as the Chromogenic Reagents. Gently tap the microplate several times to ensure that the reagents are thoroughly mixed



13. Set the microwell reader to read at a wavelength of 450nm and measure the optical density (OD) of each well against the  $mean \ of two \ Reagent \ Blank \ wells. \ Read \ the \ microplate \ within \ a \ maximum \ of \ 10 \ minutes \ of \ the \ addition \ of \ the \ Stop \ Solution.$ 

- Test Validation Criteria Negative Control OD < 0.15
- Positive Control OD ≥ 0.30
- Positive Control OD Negative Control OD≥ 0.30

>0.30	0.15-0.30	< 0.15	Specimen OD450	Interpretative Guide
Positive	Suspect	Negative	Interpretation	re Guide

## PRODUCT DETERIORATION

The SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA) should not be used if (1) there is evidence of damage or there are other signs of deterioration contamination to the product, (2) there is evidence of leakage, (3) the expiration date has passed, (4) the package is open, or (5)

### LIMITATIONS

- 1. This test has been authorized only for the presence of total antibodies against SARS-CoV-2, not for any other viruses or
- 2. Assay results should not be used to diagnose or exclude acute COVID-19. Direct viral nucleic acid detection or antigen detection methods should be performed if acute infection is suspected
- 3. Negative results do not predude SARS-CoV-2 infection and should not be used as the sole basis for patient management
- The detection of anti-SARS-CoV-2 antibodies is dependent on the presence of the analyte in the specimen, a negative result detectable. Thus, a negative result does not preclude or rule out COVID 19 infection. can occur if the quantity of antibodies for SARS-CoV-2 present in the specimen are below the detection limit of the assay During the acute infection phase and/or for immunosuppressed patients, anti-SARS-CoV-2 antibodies might not be
- 5. Heterophilic antibodies in samples may cause interference in immunoassays. These antibodies may be present in blood are inconsistent with clinical observations indicate the need for additional testing. samples from individuals regularly exposed to animals or who have been treated with animal serum products. Results that
- 7. SARS-CoV-2 total antibodies may be below detectable levels in patients who have been exhibiting symptoms for less than 156. A positive result may not indicate previous SARS-CoV-2 infection. Consider other information including clinical history and local disease prevalence, in assessing the need for a second but different serology test to confirm an immune response.
- 8. The results obtained with this test should only be interpreted in conjunction with clinical findings and the results from other
- laboratory tests and evaluations
- 9. It is unknown at this time if the presence of antibodies to SARS-CoV-2 confers immunity to reinfection
- 10. Performance characteristics have not been evaluated for neonatal or pediatric patients
- 11. The test kit is validated for the qualitative determination of anti-SARS-CoV-2 total antibodies in human serum only the contraction of the c
- This test should not be used for blood donor screening or screening of donated blood

### WARNINGS

- Unused components should not be re-sterilized.
- Do not mix materials from different kit lot numbers
- Do not use kits beyond the expiration date.
- 4. Directions for use must be followed carefully

To be handled by trained personnel only

- 6. It must be assumed that all specimens contain infectious micro-organisms; therefore, all specimens must be handled with
- Biosafety Level 2 recommendations 7. After use, tubes and funnels must be disposed of according to laboratory regulations for infectious waste. Observe CDC

### **INDEX OF SYMBOL**

	<b>®</b>	<b>⊗</b>	REF	3)	~	LOT		Symbol
Date of manufacture	Don't use the product when the package is damaged	Please don't reuse it	Catalog number	CE mark	Temperature limit	Batch code	Use-by date	Used for
*	1	&	$\langle \Sigma \rangle$	EC REP		ND		Symbol
Avoid overexposure to the sun	Keep dry	Biological risks	Contains sufficient for <n>tests</n>	Authorized representative in the European Community	Manufacturer	In vitro diagnostic medical device	Consult instructions for use	Used for



## Hunan Runmei Gene Technology Co., Ltd.

Street, Kaifu District, Changsha, Hunan Province, China. 410153 Address: Room 401-1, Building 3, Shanhe Medical and Health Indu strial Park, No. 1048, Zhongqing Road, Shaping

### Lotus NL B.V.

EC REP

Email: peter@lotusnl.com Address: Koningin Julianaplein 10, 1e Verd, 2595AA, The Hague, Netherlands



8















SARS-CoV-2 (COVID-19) IgG Antibody Detection Kit (ELISA)

## PACKING SPECIFICATION

### INTENDED USE

 $qualitative\ detection\ of\ total\ antibodies\ (IgG)\ to\ SARS-CoV-2\ in\ human\ serum\ run\ manually.\ This\ kit\ is\ used\ for\ assisted$ The SARS-CoV-2 (COVID-19 ) IgG Antibody Detection Kit is an Enzyme-Linked Immunosorbent Assay (ELISA) intended for

### MAIN COMPONENTS

11	10	9	8	7	6	51	4	3	2	1	Number
Instructions	Microplate Sealers	Microtiter plate	Negative Control	Positive Control	Stop Solution	Chromogenic Reagent B	Chromogenic Reagent A	20 X Wash Buffer Concentrate	Specimen Diluent	Enzyme Conjugate	Composition
1	2	96T×2	1.5 ml×1 (transparent lid)	1.5 ml×1(red lid)	11ml×1(brown lid)	11ml×1(brown lid)	11ml×1(white lid)	40ml×2(white lid)	26ml×1(yellow lid)	22ml×1(red lid)	96 tests/kit

### STORAGE CONDITIONS

This product is ready for use and no further preparation is necessary. The product should be stored in its original container at 2-8°C until used. Do not overheat. Do not incubate or freeze prior to use. Improper storage will result in a loss of efficacy. Do not use after expiration date, which is clearly printed on the outer box and on each individual sterile collection unit and the

> specimen transport tube label. The unopened reagents are stable until the expiration date when stored at 2 to 8°C, and the opened kit is stable for up to 1 month from the date of opening at 2 to 8°C.

## SAMPLE REQUIREMENTS

## Applicable sample types: Serum

## Handling and storage of samples:

- Follow procedures within your laboratory to avoid cross contamination of patient specimens.
- Samples may be stored at room temperature (15-30°C) for no longer than 8 hours. If the test will not be completed within 8 hours, refrigerate the serum samples at 2-8°C for no longer than 48 hours.
- · Samples that will not be tested within the time frames outlined above should be stored at ≤ -20°C and may be subjected to 1
- As an alternative to the above, sample stability may be established by each laboratory

Collect whole blood in a serum separator tube (SST) or a red top or equivalent tube appropriate for isolation of serum. Refer to the serum collection tube manufacturer's instructions for serum preparation, including centrifugation

It is important to immediately transfer the liquid component (serum) after serum preparation into a clean polypropylene tube sized aliquots, stored at -20°C or lower if exceeding 9 days. It is important to avoid freeze-thaw cycles because this may be If the serum is not analyzed immediately, the serum should be kept at 2-8°C for up to 48 hours, apportioned into preferred detrimental to serum components. Samples which are hemolyzed, icteric or lipemic can invalidate certain tests

- l. Bring reagents to room temperature (15-30°C) for at least 30 minutes before use
- Allow for eight Blank/Control determinations (two Reagent Blank, two Negative Control, two Low Positive Control and two
- A full or partial plate may be run. Store the residual strips from a partial plate run in the original pouch and seal the entire
- 4. Determine the volume of 1X Wash Buffer needed for the run. 24 mL total of 1X Wash Buffer is needed for each full strip of 2-8°C for up to 30 days.  $\operatorname{purified}$  water thoroughly in an appropriately sized container to achieve homogeneity. The  $\operatorname{1X}$  Wash Buffer may be stored at for use with manual or automated wash. To prepare a 1X Wash Buffer, mix 1 part of the 20X Wash Buffer with 19 parts of controls and/or samples run. Volume to be prepared is (24 mL x # strips) plus sufficient excess to ensure adequate quantity
- 5. For control wells, add 50  $\mu$ L control solution directly to individual wells (except for the two Reagent Blank wells).
- 6. For sample wells, add 50 µL sample serum to each well
- Mix well by gentle shaking, cover the microplate wells with an adhesive sealer, and incubate for 30 minutes at  $37\pm2^{\circ}$ C.
- Microplate Washing: discard the liquid in the wells then fill each microwell with 300 μL of working Wash Buffer (1X). Leave preceding manual wash may be performed with an automated plate washer. washes. Firmly tap the inverted microplate on absorbent paper to thoroughly remove all residual liquid from the wells. The the wash buffer in each well for 5 seconds and then remove the wash solution from all the wells. Repeat 4 times for a total of 5
- 9. Add 100  $\mu L$  of the Enzyme Conjugate to each well at the same rate and in the same order as the samples. Cover the microplate with an adhesive sealer and incubate for 30 minutes at  $37\pm2^{\circ}$ C.
- 10. Microplate Washing: wash the microwells by following the procedure as described in step 8.
- 11. Add 50 µL each (100 µL total) of Chromogenic Reagent A and Chromogenic Reagent B, to each well at the same rate and in sealer, and incubate for 10 minutes at 37±2°C protected from direct sunlight the same order as the addition of the patient specimens. Mix well by gentle shaking, cover the microplate with an adhesive
- 12. Add 50 µL of Stop Solution to each well at the same rate and in the same order as the Chromogenic Reagents. Gently tap the microplate several times to ensure that the reagents are thoroughly mixed



13. Set the microwell reader to read at a wavelength of 450nm and measure the optical density (OD) of each well against the  $mean \ of two \ Reagent \ Blank \ wells. \ Read \ the \ microplate \ within \ a \ maximum \ of \ 10 \ minutes \ of \ the \ addition \ of \ the \ Stop \ Solution.$ 

### Test Validation Criteria

- Negative Control OD < 0.15
- Positive Control OD ≥0.30
- Positive Control OD Negative Control OD≥0.30

> 0.30	0.15-0.30	< 0.15	Specimen OD450	Interpretative Guide
Positive	Suspect	Negative	Interpretation	ve Guide

## PRODUCT DETERIORATION

there are other signs of deterioration. contamination to the product, (2) there is evidence of leakage, (3) the expiration date has passed, (4) the package is open, or <math>(5)The SARS-CoV-2 (COVID-19 ) IgG Antibody Detection Kit should not be used if (1) there is evidence of damage or

- 1. This test has been authorized only for the presence of total antibodies against SARS-CoV-2, not for any other viruses or
- 2. Assay results should not be used to diagnose or exclude acute COVID-19. Direct viral nucleic acid detection or antigen detection methods should be performed if acute infection is suspected
- Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management
- The detection of anti-SARS-CoV-2 antibodies is dependent on the presence of the analyte in the specimen, a negative result can occur if the quantity of antibodies for SARS-CoV-2 present in the specimen are below the detection limit of the assay detectable. Thus, a negative result does not preclude or rule out COVID 19 infection. During the acute infection phase and/or for immunosuppressed patients, anti-SARS-CoV-2 antibodies might not be
- 5. Heterophilic antibodies in samples may cause interference in immunoassays. These antibodies may be present in blood are inconsistent with clinical observations indicate the need for additional testing. samples from individuals regularly exposed to animals or who have been treated with animal serum products. Results that
- 6. A positive result may not indicate previous SARS-CoV-2 infection. Consider other information including clinical history and local disease prevalence, in assessing the need for a second but different serology test to confirm an immune response
- $7.~{
  m SARS ext{-}CoV ext{-}2}$  total antibodies may be below detectable levels in patients who have been exhibiting symptoms for less than 15
- 8. The results obtained with this test should only be interpreted in conjunction with clinical findings and the results from other laboratory tests and evaluations.
- 9. It is unknown at this time if the presence of antibodies to SARS-CoV-2 confers immunity to reinfection
- Performance characteristics have not been evaluated for neonatal or pediatric patients
- 11. The test kit is validated for the qualitative determination of anti-SARS-CoV-2 total antibodies in human serum only
- 12. This test should not be used for blood donor screening or screening of donated blood

### WARNINGS

- Unused components should not be re-sterilized.
- Do not mix materials from different kit lot numbers
- Do not use kits beyond the expiration date.
- To be handled by trained personnel only 4. Directions for use must be followed carefully
- 6. It must be assumed that all specimens contain infectious micro-organisms; therefore, all specimens must be handled with
- Biosafety Level 2 recommendations 7. After use, tubes and funnels must be disposed of according to laboratory regulations for infectious waste. Observe CDC

### INDEX OF SYMBOL

M.	<b>Ø</b>	<b>(S)</b>	REF	3)	~	LOT	<b>I</b> XI	Symbol
Date of manufacture	Don't use the product when the package is damaged	Please don't reuse it	Catalog number	CE mark	Temperature limit	Batch code	Use-by date	Used for
*	1	®	$\langle \Sigma \rangle$	EC REP	E.	IVD	<b>=</b>	Symbol
Avoid overexposure to the sun	Keep dry	Biological risks	Contains sufficient for <n>tests</n>	Authorized representative in the European Community	Manufacturer	In vitro diagnostic medical device	Consult instructions for use	Used for



## Hunan Runmei Gene Technology Co., Ltd.

Tel: +86-731-89919680 Street, Kaifu District, Changsha, Hunan Province, China. 410153 Address: Room 401-1, Building 3, Shanhe Medical and Health Indo strial Park, No. 1048, Zhongqing Road, Shaping

### Lotus NL B.V.

EC REP

Address : Koningin Julianaplein 10, 1e Verd, 2595AA, The Hague, Netherland

### **Inspection Report**



文件编号: RM-R07-002-1.0

### Finished Product Inspection Report

Report No.20120101-1

Product Name	SARS-C	oV-2 (COVID-19) Ig	G Antibody I	Detection	Kit (ELISA)		
Cat#	QY-E-E1001	Specification	192T	LOT	20120101		
Inspection Department	Quality Department	Delivery Date		Decem	ber 1, 2020		
Inspection Department	Quality Department	Inspection Date	December 1, 2020				
Basis of Inspection	Basis of Inspection Quality Standard of SARS-CoV-2 (COV				ction Kit (ELISA)		
	Quali	ity Inspection Situat	ion				
Inspection Items	Quality Inst	pection		Inspecti	ion Results		
Physical Inspection	marked and not instructions are clear a	instructions are clear and complete, and the product name, batch number and			clearly marked and no damage. The instructions are clear and complete, and the		
Detection of coincidence rate of positive and negative reference products	The test results of the areference samples must and no false negatives. The test results of the areference samples must and no false positives.	t all be positive ; 4 negative	The test results of 4 positive reference samples were all positive and no false negatives; The test results of 4 negative reference samples were all negative and no false positives.				
Sensitivity Detection	1. If there is a national it shall be tested w standard product, and be able to be detected 2. Detect with actual detection rate is 100%.	with the national d it is required to ; samples, and the			s of 6 positive samples no false negatives.		
Specific Detection	Check for cross-reactive antibodies from species homology.				no cross-reactivity with by infection with the		
Precision Detection	and the results are con	sistent. The coeffici	ent of variation	on CV≤3%			
Conclusion	standards.	reagents is 检验专用章	qualifie	ed and	l meets quality		
Inspector	Jiao Jia	ang	Reviewer		Yulin Wen		
Inspection Date	December		Review Date		December 1, 2020		



### Finished Product Inspection Report

Report No.20120501-1

Product Name	SARS-C	oV-2 (COVID-19) Ig	M Antibody I	Detection	Kit (ELISA)
Cat#	QY-E-E1002	Specification	192T	LOT	20120105
Inspection Department	Quality Department	Delivery Date		Decem	ber 5, 2020
Inspection Department	Quality Department	Inspection Date	December 5, 2020		
Basis of Inspection	Quality Standard of SA	RS-CoV-2 (COVID-	19) IgM Antib	ody Dete	ction Kit (ELISA)
	Quali	ity Inspection Situat	tion		
Inspection Items	Quality Insp	pection		Inspect	on Results
Physical Inspection	marked and not instructions are clear a	instructions are clear and complete, and the product name, batch number and			a complete appearance, d no damage. The and complete, and the number and expiry date
Detection of coincidence rate of positive and negative reference products	The test results of the a reference samples must and no false negatives. The test results of the a reference samples must and no false positives.	st all be positive ; 4 negative	are clear.  The test results of 4 positive reference sample were all positive and no false negatives; The test results of 4 negative reference samples were all negative and no false positives.		
Sensitivity Detection	1. If there is a national it shall be tested w standard product, and be able to be detected 2. Detect with actual detection rate is 100%.	with the national d it is required to ; samples, and the			of 6 positive samples no false negatives.
Specific Detection	Check for cross-reactive antibodies from species homology.				no cross-reactivity with by infection with the
Precision Detection	Randomly check 10 po and the results are con				I. Repeat the test 3 times b.
Conclusion	standard	reagents is 验专用章	qualifie	ed and	I meets quality
Inspector	Jiao Jia	ang	Reviewer		Yulin Wen
Inspection Date	December	5, 2020	Review Date		December 5, 2020

### Declaration of manufacturer's qualification



### 对外贸易经营者备案登记表

备案登记表编号: 03604216

统一社会信用代码: 91430105MA4PJ2NG30 进出口企业代码: \_\_\_\_\_

经营者中文名称	湖南润美基因科技有限公司					
经营者英文名称	HuNan RumMei Gene	Technology Co.,LTD				
组织机构代码		经营者类型 (由备案登记机关填 <sup>5</sup>	有限责任公司			
住所	长沙市开福区沙坪街道 401-1房	长沙市开福区沙坪街道中青路1048号山河医药健康产业园标准厂房3栋 401-1房				
经营场所 (中文)	长沙市开福区沙坪街道中青路1048号山河医药健康产业园标准厂房3栋 401-1房					
经营场所 (英文)	Room 401, Building No.3 in ChangSha Medical and Health Industrial Park. No.1048 Zhong Qing Road. Kai Fu District. ChangSha. HuNan Prov., P.R. China					
联系电话	0731-89919680	联系传真	0731-89919680			
邮政编码	410153	电子邮箱	hnrunmei@163.com			
工商登记注册日期	2018-4-28	工商登记注册号				

### 依法办理工商登记的企业还须填写以下内容

企业法定代表人姓名	龚剑	有效证件号	452329197710061411
注册资金	壹仟万元		(折美元)

### 依法办理工商登记的外国(地区)企业或个体工商户(独资经营者)还须填写以下内容

企业法定代表人/ 个体工商负责人姓名	有效证件号
企业资产/个人财产	(折美元)

备注

填表前请认真阅读背面的条款,并由企业法定代表人或个体工商负责人签字、盖章。



### 出入境检验检疫报检企业备案表

编号

备案类别:▽自理报检企业□代理报检企业□快件运营企业 备案号: 4307100114

		▼ 10 × 10 × 10 × 10 × 10 × 10 × 10 × 10	正可以门边百	正业 备条号: 430/100114		
企业名称	中文	湖南润美基因科技	有限公司			
11. 11. 11. 11.	英文	HuNan Runmei Gene	Van Runmei Gene Technology Co., LTD			
住所	长沙市 3栋401	开福区沙坪街道中青 -1房	路1048号山河	<b>『医药健康产业园标准厂房</b>		
经营场所	长沙市 3栋401-	开福区沙坪街道中青 -1房	路1048号山河	「医药健康产业园标准厂房		
企业性质	私营企业		企业类别	有自营权的生产企业		
统一社会 信用代码	9143010	05MA4PJ2NG30	营业执照号	91430105MA4PJ2NG30		
组织机 构代码	MA4PJ2N	dG3	行政区划	430105		
法定代表人 /负责人	龚剑		有效证件号	452329197710061411		
联系人	林小美		联系电话	0731-89919680		
电子邮箱	hnrunme	i@163. com				

### 快件运营企业备案还须填写以下内容

快递业务经	
营许可证号	
经营范围	

报检专用章印模、中英文原产地签证印章:(另附页) 填表前请认真阅读背面的条款,并由企业法定代表人/负责人签字、盖章。

> 备案机构(签章) 2018年8 月15日

**建筑金属** 

中华人民共和国海关总

监制

珊

# 重要提示

关

樂

国识证证证

华人民共和报关单位注册登

#

报关单位应当在每年6月30日前向海关提交《报关单位注册信息年度报告》,不再另行通知。

海关注册编码: 4301967759

组织机构代码: MA4PJ2NG3

业 名 称: 湖南润美基因科技有限公司

会

企业住所: 长沙市开福区沙坪街道中青路1048号山河医药健康产业园标准厂房3栋401-1房

企业经营类别; 进出口货物收发货人

注册登记日期: 2018年8月15日

法定代表人: 龚剑

有效期:长期



QG07

### bsi.



### Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that: Hunan Runmei Gene Technology Co., Ltd.

Room 401-1, Building 3

Shanhe Medical and Health Industrial Park 湖南省 No. 1048, Zhongqing Road, Shaping Street 长沙市

Kaifu District, Changsha

Hunan 410153 China

湖南润美基因科技有限公司

开福区沙坪街道

中青路1048号山河医药健康产业园

标准厂房3栋401-1房 邮编: 410153

Holds Certificate No: MD 729427

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

> Manufacture and Distribution of Nucleic Acid Detection Kit (Fluorescent RT-PCR Method) for Diagnosis of Viral Infections.

用于诊断病毒感染的核酸检测试剂盒(荧光 RT-PCR 方法)的制造和分销。

For and on behalf of BSI:

Gary E Slack, Senior Vice President - Medical Devices

Original Registration Date: 2020-06-24 Effective Date: 2020-06-24 Latest Revision Date: 2020-06-24 Expiry Date: 2023-06-23





Page: 1 of 1

...making excellence a habit."

This certificate was issued electronically and remains the property of BSI and is bound by the conditions of contract. An electronic certificate can be authenticated online.

Printed copies can be validated at www.bsi-global.com/ClientDirectory or telephone +86 10 8507 3000.

Information and Contact: BSI, John M. Keynesplein 9, 1066 EP Amsterdam The Netherlands. Tel: +31 (0) 20 3460 780 BSI Group The Netherlands B.V., registered in the Netherlands under number 33264284, at John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands A Member of the BSI Group of Companies.



### 质量管理体系认证证书

### 湖南润美基因科技有限公司

书 注 册 号: 46820Q50057ROS

社会信用代码: 91430105MA4PJ2NG30

注 册 址:湖南省长沙市开福区沙坪街道中青路 1048 号山河医药健康产

业园标准厂房 3 栋 401-1 房

P. C 410000


管理体系符合: GB/T 19001-2016 idt IS09001:2015

证书覆盖范围:资质范围内核酸提取或纯化试剂、一次性使用采样器的研发、

生产和销售

iF 颁 期: 2020年06月05日

至: 2023年06月04日 有 效 期








证书颁发后,3年有限期内要至少接受2次监督审核。证书即时有效性可通过网站查询www.ybtc.org.cn.

>>>>>>>>

地址:长沙市开福区福元西路220号英祥苑2期1栋940-941房







### QUALITY MANAGEMENT SYSTEM CERTIFICATION

### Hunan Runmei Gene Technology Co., Ltd.

Registration No: 46820Q50057R0S

Organization Code: 91430105MA4PJ2NG30

Registration Address: Room 401-1, Building 3, Shanhe Medical and Health Industrial

Park, No. 1048, Zhongqing Road, Shaping Street, Kaifu District,

Changsha, Hunan Province, China. P. C 410000

In conformity with: GB/T 19001-2016 idt IS09001:2015

Certification scope: R&D, production and sales of Virus Nucleic Acid Extraction

Kit or Nucleic Acid Detection Kit, Single-use samplers


within the scope of qualifications.

Issue Date:

Jun 05, 2020

Expiry Date:

Jun 04, 2023





>>>>>>>>



After this certificate is issued, there should be at least 2 surveillance audits within the 3 year period of validity the current validity of the certificate can be checked on (www.ybtc.org.cn). The certificate information is available on the official website of the National Certification and Accreditation Administration (www.cnca.gov.cn). It is also available by scanning the two-dimensional code at the bottom right corner.

Address: 220 Fuyuan West Road, Kaifu District, Changsha City Hunan



### **CE Certification**



> Retouradres Postbus 16114 2500 BC Den Haag

Lotus NL B.V. T.a.v. de heer X. Wei Koningin Julianaplein 10 2595 AA 's-Gravenhage

Datum: 27 november 2020

Betreft: aanmelding In-vitro diagnostica

Geachte heer Wei,

Op 17 november 2020 ontving ik uw notificatie krachtens artikel 4, eerste lid van het Nederlandse Besluit in-vitro diagnostica (BIVD) om onder de bedrijfsnaam Hunan Runmei Gene Technology Co., Ltd met Europees gemachtigde Lotus NL B.V. onderstaande producten als in-vitro diagnostica op de Europese markt te Correspondentie uitsluitend brengen.

De producten staan geregistreerd als in-vitro diagnostica onder nummer:

**Full Automatic Nucleic Acid Extract Instrument.** (geen merknaam) (NL-CA002-2020-54351) SARS-CoV-2 (COVID-19) IgG Antibody Detection Kit (ELISA), SARS-CoV-2 (COVID-19) IgM Antibody Detection Kit (ELISA), SARS-CoV-2 (COVID-19) /Influenza A /B Virus Nucleic Acid Detection Kit(Fluorescence RT-PCR Method), (geen merknaam) (NL-CA002-2020-54350)

Hiermee heeft u voldaan aan uw verplichting op grond van artikel 4, BIVD.

In alle verdere correspondentie betreffende bovenvermelde producten verzoek ik u deze nummers te vermelden. Aan deze nummers kunnen geen verdere rechten ontleend worden, ze dienen alleen om de notificatie administratief te vergemakkelijken.

De registratie van in-vitro diagnostica als medisch hulpmiddel op grond van de Classificatiecriteria (Bijlage II) bij Richtlijn 98/79/EG betreffende medische hulpmiddelen voor in-vitro diagnostiek is onderhevig aan mogelijke revisies van Europese regelgeving inzake de classificatie van medische hulpmiddelen en aan voortschrijdend wetenschappelijk inzicht (zie artikel artikel 10, eerste lid van Richtlijn 98/79/EG).

**Farmatec** 

Bezoekadres: Hoftoren Rijnstraat 50 2515 XP Den Haag T 070 340 6161

http://hulpmiddelen.farmatec.nl

Inlichtingen bij: T.I. van Langeveld - Baas

medische\_hulpmiddelen@ minvws.nl

Ons kenmerk: CIBG-20205542

Biilagen

Uw aanvraag 17 november 2020

richten aan het retouradres met vermelding van de datum en het kenmerk van deze brief.

Pagina 1 van 2

Notificatie van in-vitro diagnostische medische hulpmiddelen impliceert dat de fabrikant, Hunan Runmei Gene Technology Co., Ltd de CE-conformiteitsmarkering heeft aangebracht op de desbetreffende producten alvorens deze in een EU-lidstaat in de handel te brengen. Zodoende garandeert Lotus NL B.V. dat de in-vitro diagnostica voldoen aan de essentiële eisen zoals opgenomen in bijlage I bij Richtlijn 98/79/EG (en in het daarmee corresponderende onderdeel 1 bij het besluit)

Volledigheidshalve wijzen wij u erop dat een in-vitro diagnosticum moet voldoen aan de eisen uit het BIVD. Het BIVD is gebaseerd op Richtlijn voor in-vitro diagnostiek, 98/79/EG. Met name wijzen wij u op de Nederlandse-taaleis zoals deze in Nederland geldt, de eisen voor het ter beschikking houden van de technische documentatie en de plicht tot het hebben van een Post Marketing Surveillance- en vigilantiesysteem.

Tot slot merk ik op dat met uw notificatie - de administratieve notificatie als fabrikant - en deze brief geen sprake is van een oordeel over de status of kwalificatie van uw product: notificering betekent niet dat daadwerkelijk sprake is van een in-vitro diagnosticum in de zin van de onderhavige wet- en regelgeving. In voorkomende gevallen kan de Inspectie Gezondheidszorg en Jeugd (IGJ), belast met het toezicht op de naleving van het bij of krachtens de wet bepaalde, een standpunt innemen over de status van een product, waarbij het volgens vaste jurisprudentie uiteindelijk aan de nationale rechter is om te bepalen of een product onder de definitie van in-vitro diagnosticum valt.

De Minister voor Medische Zorg en Sport, namens deze,

Afdelingshoofd Farmatec

Dr. M.J. van de Velde





Report Number: QIP-ASI209100

Audit Date :

09 Apr., 2020

This report is issued by Focus Technology Co., Ltd. (Made-in-China.com) and the supervising inspectorate (SGS-CSTC Standards Technical Services Co., Ltd.) to confirm that:

Company Name : Hunan Rummei Gene Technology Co., Ltd.

湖南润美基因科技有限公司

Showroom http://runmeigene.en.made-in-china.com

Address Room 401-1, Building 3, Standard Workshop, Shanhe Medical and

Health Industrial Park, No. 1048, Zhongging Road, Shaping Street, Kaifu District, Changsha City, Hunan Province, China

**Product** Virus Nucleic Acid Extraction Kit or Nucleic Acid Detection Kit.

Single-use Samplers, New Coronavirus COVID-19 Nucleic Acid Detection Kit(Fluorescent RT-PCR Method), New Coronavirus COVID-19 Antibody Detection Kit (Colloidal Gold), Real Time

Fluorescence Quantitative PCR Detector, Portable Microplate Reader, Rapid Detection Kit, Nucleic Acid Detection Kit(Fluorescent RT-PCR

Method), Antibody Detection Kit (ELISA), New Coronavirus (COVID-19) Antibody ELISA Kit, New Coronavirus COVID-19 Detection Kit (ELISA), New Coronavirus COVID-19 Detection Kit (Colloidal Gold), Canine Parvovirus Antibody Detection Kit (Colloidal Gold), Porcine Reproductive and Respiratory Syndrome Virus Detection Kit (ELISA), Avian Influenza Virus H5 Subtype Nucleic Acid

**Detection Kit (Fluorescent RT-PCR Method)** 

### has been on site audited for the Following Scope of Activity

- 1. General Information
- 2. Foreign Trade Capacity
- 3. Product Research & Development Capacity
- 4. Management System and Product Certification
- 5. Production Capacity & Quality Control
- 6. Working Environment
- 7. Energy Saving and Emission Reduction
- 8. Photos

### **General Comments:**

Hunan Rummei Gene Technology Co., Ltd. is a manufacturer and trader combined company, they 2018, located in Room 401-1, Building 3, Standard Workshop, Shanhe Medical and Health Faturation Zhongqing Road, Shaping Street, Kaifu District, Changsha City, Hunan Province, China The company brand, and they have obtained CE certificates and test report for products. Strong research team, and enough tests on the products to ensure the quality of the products and their goods will be delivered after stri quality inspection.



Page No.: 1 of 20 5/F, B-4 Building, Zijin (Baixia) Technology Incubation Special Park, No. 10

a Road, Nanjing, China 210014 t (86-25) 87128385 f (86-25) 83407773 中国·南京·秦淮区光华路1号紫金白下创业特别社区4号楼B帕5楼 邮编: 210014 t (86-25) 87128385 f (86-25) 83407773

Member of the SGS Group (SGS SA)



e as.cn@sgs.com



Sign for and on behalf of SGS-CSTC Standards Technical Services Co., Ltd.





Attention: To check the authenticity of pating (Moscileo resolute of 20 certificate, please contact as at telephone: (86-75) 8307 1443, or email: CN\_Doscheck@sgs.com Page No.: 2 07 20 tt (86-25) 87128385 f (86-25) 83407773 www.sgsgroup.com.cn 中国・南京・秦淮区光华路1号紫金白下创业特别社区4号楼D植S楼 邮编: 210014 tt (86-25) 87128385 f (86-25) 83407773 e as.cn@sgs.com

SGS

SGS No: QIP-ASI209100



### SUPPLIER ASSESSMENT REPORT

Audited Company	Hunan Rummei Gene Technology Co., Ltd.
Audited Site:	Room 401-1, Building 3, Standard Workshop, Shanhe Medical and Health Industrial Park, No. 1048, Zhongqing Road, Shaping Street, Kaifu District, Changsha City, Hunan Province, China

Consigner of Assessment	Made-in-China.com		
Audit Type	☐ Re-audit		
Audit Date	09 Apr., 2020	Verify Report	www.sgs.com/ecv
Auditor	Vitor Chen	Reviewed by	Toby Han

### CONTENTS

### Part A: General Information

- Section 1: Company Overview
- Section 2: Human Resources

### Part B: Foreign Trade Capacity

- Section 1: Export Overall Situation
- Section 2: Export Business Capacity
- Section 3: Supplier Management
- Section 4: After-sales Service Capacity

### Part C: Product Research & Development Capacity

Section 1: Product Research & Development Capacity

### Part D: Management System and Product Certification

Section 1: Management System(s) and Product Certification

### Part E: Production Capacity & Quality Control

- Section 1: Production Capacity Section
- Section 2: Production Process Control

### Part F: Financial Position

- Section 1: Financial Data
- Section 2: Key Performance Indications
- Section 3: Banking
- Section 4: Product Insurance

### Part G: Working Environment

Section 1: Working Environment

### Part H: Energy Saving and Emission Reduction

- Section 1: Environmental Management
- Section 2: Water, Gas and Noise Control

### Part I: Industry Information

Section 1: Industry Information

Part J: Photos

Section 1: Photos of Documents



Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible at <a href="http://www.sqs.com/en/Terms-and-Conditions.aepx">http://www.sqs.com/en/Terms-and-Conditions.aepx</a> Attention is drawn to the limitation of isability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safely and readily accessible portions of the consignment and reflects the Company's Indiang sat the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction focuments. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of

Attention: To check the authenticity of testing financial reports certificate, please or email: CN Daccheck@sgs.com Page No.: 3 of 20

5所.84 Building, Zijin [Baixia] Technology Insubration Special Park, No.1 Guanghus Road, Manjing, China 210014 t (88-25) 87128385 f (88-25) 83407773 www.sggroup.com.cn 中国・南京・泰淮区光年路1号景金白下创业特别社区4号楼即植5楼 邮编: 210014 t (88-25) 87128385 f (88-25) 83407773 e a s.cn@sgs.com





Section 2: Photos of Company





t (86-25) 87128385 f (86-25) 83407773 www.sgsgroup.com.cn t (86-25) 87128385 f (86-25) 83407773 e as.cn@sgs.com

SGS

SGS No: QIP-ASI209100



### Part A: General Information

### **Section 1: Company Overview**

1.1 Legal Validity			
Does the company have a valid business license?	☐ Yes ☐ No ☐ Others	Registration Number	91430105MA4PJ2NG30
Year of established	28 Apr., 2018	Valid Date	27 Apr., 2068
Registered address	Room 401-1, Building 3, Standard Park, No. 1048, Zhongqing Road Hunan Province, China		
Actual address	Room 401-1, Building 3, Standard Park, No. 1048, Zhongqing Road Hunan Province, China	Workshop, Shanh I, Shaping Street,	e Medical and Health Industrial Kaifu District, Changsha City,
Does the company in abnormal operation status list of industrial and commercial bureau?	No		
Registered capital	RMB 10,000,000		
Name of legal representative	Mr. Jian Gong		
Business scope	Medical research and experiments analytical instruments, II class: 68 a class of medical equipment technical services; Technical consideration and exchange services for medical devices; Eservices for medical devices; Eservices, exchange services, trincubation and transformation of so operation of health care industry prediagnostic reagent, II class: 6840 biological products; Import and excon its own or on its own behalf, expressived by the state to operate biological products, medical applications analytical instruments, products sales.	340 in vitro diagnos research and development and medical institutes for medical street for medical street for services; cientific research a clinical test analyst port of all kinds of except for commodities or prohibited by aratus and instruit	stic reagent, biological products, velopment; Medical inspection al examination; Development of trument technology; Technical devices; Technology transfer velopment services, consulting Research and development, chievements; Management and agement; II class: 6840 in vitro is instrument, the production of commodities and technologies which are by the state; Kind of veterinary ments, II class: 6840 clinical
1.2 Basic Information			
Contact person	Ms. Ann Lin		
Phone number	0086-731-89919680	Fax number	0086-731-89919680
URL/Web address	http://runmeigene.en.made-in-chin	a.com	. 19
Company type		Company Corporation	多类基因
Type of ownership			reign joint venture nolly foreign-owned enterprises
Associated company	No		<b>有人</b>
1 17-21 - 12-21			30



Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible. <a href="http://www.sps.com/en/Terms-and-Conditions.aspx">http://www.sps.com/en/Terms-and-Conditions.aspx</a> Attention is drawn to the limitation of liability, indemnification and jurisdiction issue defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of its safely and readily accessible portions of the consignment and reflects the Company's findings at the time of its intervention only an within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exoneral parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized alteration forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent the law.

SGS

SGS No: QIP-ASI209100



Products manufactured / sold scope

Virus Nucleic Acid Extraction Kit or Nucleic Acid Detection Kit, Single-use Samplers, New Coronavirus COVID-19 Nucleic Acid Detection Kit(Fluorescent RT-PCR Method), New Coronavirus COVID-19 Antibody Detection Kit (Colloidal Gold), Real Time Fluorescence Quantitative PCR Detector, Portable Microplate Reader, Rapid Detection Kit, Nucleic Acid Detection Kit(Fluorescent RT-PCR Method), Antibody Detection Kit (ELISA), New Coronavirus (COVID-19) Antibody ELISA Kit, New Coronavirus COVID-19 Detection Kit (ELISA), New Coronavirus COVID-19 Detection Kit (Colloidal Gold), Porcine Reproductive and Respiratory Syndrome Virus Detection Kit (ELISA), Avian Influenza Virus H5 Subtype Nucleic Acid Detection Kit (Fluorescent RT-PCR Method)

4	3	Co	man	amy/	RII	ildin	or le	form	nati	ion

According to:

☐ Land certificate

☐ Lease agreement

☐ Real estate certificate

□ Lease agreement □ Observation Estimated on site
 The company area 1,000 square meters

The land occupies Confidential square meters. The offices occupy 100 square meters. The workshops occupy 800 square meters.





Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible a <a href="http://www.ags.com/en/Terms-and-Conditions.ags.xy.Attention">http://www.ags.com/en/Terms-and-Conditions.ags.xy.Attention</a> is drawn to the limitation of biblitity, indemnification and jurisdiction issue defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safely and readily accessible portions of the consignment and reflects the Company's intended intended the readily accessible portions of the consignment and reflects the Company's intended intended the readily accessible portion of the content of appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

remail: CN. Doccheck the authenticity of tacting /insecting report of the control of the control

中国、南京、泰淮区光华路1号紫金白下创业特别社区4号楼8幢5楼 邮编: 210014


t (86-25) 87128385 f (86-25) 83407773 t (86-25) 87128385 f (86-25) 83407773

e as.cn@sgs.com





### Section 2: Human Resources







Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible at <a href="http://www.sgs.com/en/Terms-and-Conditions.agp.">http://www.sgs.com/en/Terms-and-Conditions.agp.</a> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safety and readily accessible portions of the consignment and reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

Attention: To check the authenticity of pating in specifies repeat of 20 certificate, please contact us at telephone: (86-75) 8307 1443, or email: CM.Doccheck@ags.com Page No.: 70 120 to (86-25) 87128385 f (86-25) 83407773 www.sgsgroup.com.cn 中国・南京・幕准区光华路1号景全白下创业特别社区4号楼5幢5楼 邮编: 210014 t (86-25) 87128385 f (86-25) 83407773 e e as.cn@sgs.com

SGS

SGS No: QIP-ASI209100




### Part B: Foreign Trade Capacity

### **Section 1: Export Overall Situation**

1.1 Export Overall Situation	
Does the company have a valid Import and Export license?	⊠ Yes □ No
The import and export enterprise code.	91430105MA4PJ2NG30
The number of foreign trading staff with relevant trading experience.	☐ within 1 year staff ☐ 1-5 years staff ☐ 6-10 years 4 staffs ☐ over 10 years staff ☐ Total 4 staffs
The language freely used by foreign trade staff	☐ English ☐ others
Annual revenue of previous year	Confidential
Annual export revenue of previous year	Confidential
Estimated export revenue for this year.	Confidential
Overseas agent / branch	☐ Yes ☐ No
Nearest port	Shenzhen Port
Acceptable quotation terms	FOB CIF CFR Other: UPS, DHL
Acceptable payment terms	☐ LC
Average lead time (Peak Season)	☑ within 15 workday   ☐ one month   ☐ 2-3 months     ☐ 4-6 months   ☐ 6-12 months   ☐ more time
Average lead time (Off Season)	⊠ within 15 workday   □ one month   □ 2-3 months     □ 4-6 months   □ 6-12 months   □ more time

### Section 2: Export Business Capacity

2.1 Market Distribution (please list top three areas)				
Market	Main Product	Main client		
☐ North America				
☐ South America				
☐ Europe				
☐ Southeast Asia/ Mideast				
☐ Africa				
☐ East Asia (Japan/ South Korea)				
☐ Australia				



SGS

SGS No: QIP-ASI209100



☑ Domestic	Virus Nucleic Acid Extraction Kit or Nucleic Acid Detection Kit, Single-use Samplers, New Coronavirus COVID-19 Nucleic Acid Detection Kit(Fluorescent RT-PCR Method), New Coronavirus COVID-19 Antibody Detection Kit (Colloidal Gold), Real Time Fluorescence Quantitative PCR Detector, Portable Microplate Reader, Rapid Detection Kit, Nucleic Acid Detection Kit(Fluorescent RT-PCR Method), Antibody Detection Kit (ELISA), New Coronavirus (COVID-19) Antibody ELISA Kit, New Coronavirus COVID-19 Detection Kit (ELISA), New Coronavirus COVID-19 Detection Kit (Colloidal Gold), Canine Parvovirus Antibody Detection Kit (Colloidal Gold), Porcine Reproductive and Respiratory Syndrome Virus Detection Kit (ELISA), Avian Influenza Virus H5 Subtype Nucleic Acid Detection Kit (Fluorescent RT-PCR Method)	Confidential
Others		





The law. Attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention: To check the authenticity of earling (Inspection report) attention report (Inspection report) atten







### **Section 3: Supplier Management**

ltem	Content	Observations /Comments
1	Does the company establish and implement an effective suppliers' assessment procedure?	☐ Have the written procedures and followed records     ☐ Have the written procedures but no records     ☐ Have relevant records without written procedure     ☐ No written procedures or followed records     ☐ Other
2	Does the company have an updated list of approved suppliers?	<ul> <li>☑ The approved suppliers list was updated in2019</li> <li>☐ Have the written suppliers without approved signature of date.</li> <li>☐ Provided some suppliers names</li> <li>☐ No approved suppliers list</li> <li>☐ Other</li> </ul>

### Section 4: After-sales Service Capacity

Item	Content	Observations /Comments
1	Is there a procedure to conduct random product inspection after final packaging in place?	□ Have clear standards and written inspection records     □ No written standards but had inspection reports     □ Have the procedures but no inspection records     □ It's not necessary to carry out the inspection     □ Other
2	Is there a clear procedure for handling customer complaints?	<ul> <li>☐ Has the clear procedure and followed records</li> <li>☐ Has the procedure but no written records.</li> <li>☐ No written procedures or records.</li> <li>☐ Other</li> </ul>
3	Can the finished/packaged product be traced by lot identification to the appropriate raw materials test reports?	☐ Have the procedures to trace the raw materials.     ☐ Can trace main materials     ☐ Can trace production date.     ☐ Can't trace products     ☐ Other
4	Are corrective & preventive actions mechanism established and implemented effectively (including the suppliers/ sub-contractors control, incoming inspection, process control, final inspection and customer complaint)?	<ul> <li>☐ Has the clear procedure and followed records</li> <li>☐ Has the procedure but no written records.</li> <li>☐ No written procedures or records.</li> <li>☐ Other</li> </ul>





Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible a <a href="http://www.sgs.com/en/Terms-and-Conditions.apx.Attention">http://www.sgs.com/en/Terms-and-Conditions.apx.Attention</a> is drawn to the limitation of bibility, indemnification and jurisdiction is use defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safety and readily accessible portions of the consignment and reflects the Company's limited to visual examination of the width of the safety and readily accessible portions of the consignment and reflects the Company's limited to visual examination of within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized alteration forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

or email: CNL Doscheck@eas.com Page No.: 10 00 20

Fig. 4 No.: 10 00 20

Fig. 5 No.: 10 00 20

Fig. 4 No.: 10





### Part C: Product Research & Development Capacity

The amount of R&D and relevant working experience.	☐ within 1 year staff ☐ 1-5 years staff ☐ 6-10 years staff ☐ over 10 years 4 staffs  Total 4 engineers
What is the main job responsibility for R&D engineers?	The main job responsibility is in charge of customers request new product design and development.
Is there any relevant design input, output, review, verification and validation documentation available for auditor to review?	Yes Design per market trend and client's requirement.
Is there any special software or instrument used by the R&D staffs during the design process of new products?  If yes, please list the main software or instrument.	No
Does the company have an effective design change control procedure in place?	Yes They will modify their design per client's requirement.
Please list the patent certificates and qualification license.	Nil





Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible at <a href="http://www.sgs.com/en/Trems-and-Conditions.aspx">http://www.sgs.com/en/Trems-and-Conditions.aspx</a> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safety and readily accessible portions of the consignment and reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.





### Part D: Management System and Product Certification

Management system certification	⊠Others
managamon ayatam ocitiloation	Certificate Name: Certificate of Good Manufacturing Practices
	For Animal Drugs
	No.: 18001
	Issued by: Department of agriculture and rural areas of Hunan province
	Issued Date: 14 Feb., 2020 Valid Until: 13 Feb., 2025
	Scope: Molecular biological diagnostic products (class B)
Product certification	☑ CE
	Certificate Name: CE
	No.: R A001 49/B Rev.01 Product Name: New Coronavirus COVID-19 Detection Kit
	(Colloidal Gold)
	Model: N/A Standard: 98/79/EC
	Issued by: Medpath Gmbh
	Issue Date: 26 Mar., 2020
	Certificate Name: CE
	No.: R A001 49 Rev.01
	Product Name: New Coronavirus COVID-19 Nucleic Acid Detection Kit(Fluorescent RT-PCR Method)
	Model: N/A Standard: 98/79/EC
	Issued by: Medpath Gmbh
	Issue Date: 17 Mar., 2020
	□ UL
	□ ccc
	□ RoHS
	□ FCC
	☐ Others
	□ NIL
Test reports for raw materials	RoHS
	□ Reach
	□ Others
	NIL →
	是 型
	The same of the sa




Page No.: 12 of 20 





### Part E: Production Capacity & Quality Control

### **Section 1: Production Capacity**





Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible a <a href="http://www.sgs.com/en/Terms-and-Conditions.aspx">http://www.sgs.com/en/Terms-and-Conditions.aspx</a> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safety and readily accessible portions of the consignment and reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction form exercising all their rights and obligations under the transaction documents, unjust or uppearance of this document is unlawful and offenders may be prosecuted to the fullest extent or repearance of this document is unlawful and offenders may be prosecuted to the fullest extent or

Attention: To check the authenticity of sating (where the authenticity of

SGS

SGS No: QIP-ASI209100



in the second second	Skimming Line	China	Confidential	1
	Testing Line	China	Confidential	2
	Freedom EVOlyzer	China	Confidential	1
	Microplate Reader	China	Confidential	1
S. Santania	Washing Machine	China	Confidential	1
	High Temperature Sterilizer	China	Confidential	1





Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible at <a href="http://www.aps.com/en/Terms-and-Conditions.apx.">http://www.aps.com/en/Terms-and-Conditions.apx.</a> Attention is drawn to the limitation of bibility, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safely and readily accessible portions of the consignment and reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized attention, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent or

Attention: To check the authenticity of pating (wapect) 2 reperiod certificate, please contact us at telephone: (86-755) 8307 1443 or email: CN\_Doccheck@ess.com Page No.: 14 off 20 certificate, please contact us at telephone: (86-755) 8307 1443 or email: CN\_Doccheck@ess.com | 156-84 8316, Zim (88-25) 87128385 | (86-25) 83407773 | www.sqsgroup.com.cn

SF,84Bullding,Zijn (Britis) Technology Incubation Special Park, No.1 Guanghua Road, Nanjing, China 210014 t (86-25) 87128385 f (86-25) 83407773 www.sgsgroup.com 中国・南京・秦淮区光华路1号紫金白下領业特別社区4号楼B幡5楼 邮箱: 210014 t (86-25) 87128385 f (86-25) 83407773 e as.cn@sgs.co





### **Section 2: Production Process Control**

tem	Content	Observations /Comments
1	Product R&D capacity	<ul><li>☑ Own brand</li><li>☑ ODM</li><li>☑ OEM</li></ul>
2	Are the environmental conditions, such as tidiness and cleanliness being controlled and suitable for the operation performed?	<ul><li>□ Very tidy</li><li>☑ Normal</li><li>□ Need to improve</li><li>□ Very poor</li></ul>
3	Are the necessary items /documents provided at appropriate location and under control?	<ul> <li>✓ Work Instructions /procedures</li> <li>☐ Workmanship standard /acceptance</li> <li>☐ Golden sample /Approval sample</li> <li>☐ Product picture</li> <li>☐ Verbal by workshop director</li> </ul>
4	Are written instructions available for incoming material inspections /testing? Is the relevant record maintained?	<ul> <li>☐ Has instructions and uniformly followed</li> <li>☐ Has instruction but no written records</li> <li>☐ Materials checked by storage staff</li> </ul>
5	Are written inspections /testing instructions available for finished products? Is the relevant record maintained?	<ul> <li>✓ Have instructions and uniformly followed</li> <li>☐ Have instruction but no written records</li> <li>☐ Finished product checked by packing staff</li> </ul>
6	What type of inspection is used for finished products?	☐ Random inspection ☐ Visual inspection ☐ Function inspection ☐ 100% inspection ☐ Visual inspection ☐ Function inspection
7	Are non-conforming units clearly marked/ segregated to prevent accidental dispatch?	<ul> <li>☑ Marked and segregated</li> <li>☐ Segregated but not marked clearly</li> <li>☐ Not found on site</li> </ul>
8	How are the non-conforming units handled?	☐ Repaired and re-inspection ☐ Picked out ☐ Used under control ☐ Others



Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible a <a href="http://www.ags.com/en/Terms-and-Conditions.ags/">http://www.ags.com/en/Terms-and-Conditions.ags/</a> Attention is stue defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the safely and readily accessible portions of the consignment and reflects the Company's intendings at the time of its intervention only an within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerat parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized alteration forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent or the law.

Attention: To check the authenticity of cathor / Nonecting research at the please contact us at telephone: (86-755) 8307 1443, or email: CN\_Doscheck@sgs.com

| \$\tilde{A}\) | \$\tilde{A}\) | \$\tilde{A}\) | \$\tilde{A}\| | \$\tilde{A}







### Part G: Working Environment

### Section 1: Working Environment

1.1 Welf	are Benefits	
Item	Content	Observations /Comments
1	Does the company have effective procedures to verify the age of staff at the time of recruitment?	<ul> <li>☐ Has written procedure and keeps adequate age documents of workers</li> <li>☐ Has written procedure but doesn't follow records</li> <li>☐ Hasn't written procedure or follows records</li> </ul>
2	Do all workers sign employment contracts with the factory?	
3	Is statutory contribution required for all employees' social insurance (e.g. health insurance, unemployment insurance, accident insurance etc.) paid for by the enterprise?	
4	Does the company have a clear and effective policy on working hours, rest and vacations? If does, please list it.	
5	Does the company pay extra remunerations for all overtime work?	<ul> <li>☐ For all overtime work.</li> <li>☐ For official holidays</li> <li>☐ For official holidays except weekend.</li> <li>☐ No extra remunerations for overtime.</li> </ul>
6	Does the company have dormitories for staff? If yes, please describe the condition.	<ul> <li>☑ Provide dormitories for all staff</li> <li>☐ Provide dormitories for workers</li> <li>☐ Provide dormitories for management staff</li> <li>☐ No dormitories were provided.</li> <li>Describe the condition: 2 Staffs Per Room</li> </ul>
.2 Labo	or Protection	
Item	Content	Observations /Comments
1	Are there uniforms for all staff in company?	<ul><li>✓ Yes</li><li>☐ No</li><li>☐ Other</li></ul>
2	Is the emergency medical supplies enough and easily used in workshop?	<ul><li>Yes</li><li>No</li><li>Other</li></ul>
3	Does the company arrange health and safety training for new workers?	⊠ Yes □ No □ Other
4	Do the workers have the appropriate protective equipment during operation in workshop? Such as gloves, masks.	⊠ Yes □ No □ Other
5	Is there training needed and carried out for fire protection?	<ul> <li>✓ Yes</li> <li>☐ No</li> <li>☐ Other</li> </ul>



Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible at http://www.sags.com/en/Terms-and-Conditions app. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the asiety and readily accessible portions of the consignment and reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized alteration forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

Attention: To check the authenticity of pating / No.: 16 rose 20 certificate, please contact us at telephone: (86-755) 8307 1443, or email: CM. Doccheck@gs.com

SF, 84 Sulfding, Zijn (Baids) Technology Insubatins Special Park, No. 1 Guanghus Read, Nanjing, China 210014 t (86-25) 87128385 f (86-25) 83407773 www.sgsgroup.com.cn
中限,南京,秦淮区光年路1号紫金白下街业特别社区4号楼的铺路楼 邮箱: 210014 t (86-25) 87128385 f (86-25) 83407773 e as.cn@sgs.com







### Part H: Energy Saving and Emission Reduction

### **Section 1: Environmental Management**

ltem	Content	Observations /Comments
1	Environmental Management System	☐ ISO 14001 Certificate ☐ Cleaner production management ☑ NIL
2	Environmental Impact Assessment	<ul> <li>☑ The Report of Environmental impact assessment is approved by EPA Changsha in 2020.</li> <li>☑ NIL</li> </ul>
3	Check and Acceptance of Completed Constructive Projects	<ul> <li>☑ The Report Completed Constructive Projects Inspection and Acceptance is approved.</li> <li>☑ NIL</li> </ul>
4	"Three Simultaneity" for Environmental protection	

### Section 2: Water, Gas and Noise Control

2.1 Water, Gas and Noise Control		
Item	Content	Observations /Comments
1	Water-intaking	<ul> <li>□ Water-intaking license</li> <li>□ No water-intaking license</li> <li>☑ No water taken from natural water body</li> </ul>
2	Waste water	<ul> <li>□ Water-draining license or contract</li> <li>☑ Having carried out waste water treatment before draining</li> <li>□ Having carried out waste water monitoring and the result of which being within the standard limit</li> <li>□ No detail activities were found</li> </ul>
3	Emission to air	<ul> <li>☐ Air pollutant emission license</li> <li>☐ Having carried out air pollutant emission monitoring and the result of which being within the standard limit</li> <li>☑ No detail activities were found to reduce emission to air</li> </ul>
4	Classification and Recycling for solid waste	<ul> <li>☑ Having applied trash classification recycling</li> <li>☐ Having special warehouse for hazardous waste</li> <li>☐ No detail activities were found</li> </ul>
5	Noise	<ul> <li>☑ The company carried out noise monitoring and the repult of which being within the standard limit one time per year</li> <li>☑ No detail activities were found</li> </ul>



Unless otherwise agreed in writing, this document is issued by the Company under its General Conditions of Service accessible at <a href="http://www.sgs.com/en/rems-and-Conditions.agr.Attention">http://www.sgs.com/en/rems-and-Conditions.agr.Attention</a> is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon is solely limited to visual examination of the asset in the company's findings at the time of its intervention only the dwithin the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.